Arrowhead Pharmaceuticals Inc ARWR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARWR is a good fit for your portfolio.
News
-
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
-
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
-
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
-
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
-
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
-
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
-
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
Trading Information
- Previous Close Price
- $25.57
- Day Range
- $25.31–26.26
- 52-Week Range
- $20.67–39.65
- Bid/Ask
- $10.28 / $26.19
- Market Cap
- $3.18 Bil
- Volume/Avg
- 745,442 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 80.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 525
- Website
- https://www.arrowheadpharma.com
Comparables
Valuation
|
Metric
|
ARWR
|
AVIR
|
ENTA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.56 | 0.55 | 1.74 |
Price/Sales | 80.16 | — | 3.96 |
Price/Cash Flow | — | — | — |
Price/Earnings
ARWR
AVIR
ENTA
Financial Strength
|
Metric
|
ARWR
|
AVIR
|
ENTA
|
|---|---|---|---|
Quick Ratio | 8.03 | 13.11 | 6.23 |
Current Ratio | 8.31 | 13.28 | 6.43 |
Interest Coverage | −20.50 | — | −12.14 |
Quick Ratio
ARWR
AVIR
ENTA
Profitability
|
Metric
|
ARWR
|
AVIR
|
ENTA
|
|---|---|---|---|
Return on Assets (Normalized) | −49.83% | −20.62% | −25.87% |
Return on Equity (Normalized) | −116.38% | −21.76% | −50.83% |
Return on Invested Capital (Normalized) | −85.31% | −25.76% | −46.23% |
Return on Assets
ARWR
AVIR
ENTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Zjxszpzhp | Myml | $636.3 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Flbwnjm | Hrwrby | $124.4 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kbcsdvjqr | Qlgbwqz | $115.9 Bil | |||
| Moderna Inc
MRNA
| Bbzvwdnt | Cgxr | $44.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Shpgfmbyv | Tfrlrz | $32.3 Bil | |||
| argenx SE ADR
ARGX
| Lltbhcrmv | Mfyx | $25.8 Bil | |||
| BioNTech SE ADR
BNTX
| Rlbymnl | Llvm | $19.4 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kdsnjwm | Bxbzhr | $15.7 Bil | |||
| United Therapeutics Corp
UTHR
| Ymnqyqtk | Mgqm | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Qvgpbjsdb | Lzwcfy | $11.6 Bil |